Wockhardt Limited has informed the Exchange about Credit Rating
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
ICRA Limited has upgraded Wockhardt's credit ratings across all instruments and revised the outlook from 'Stable' to 'Positive'. The long-term fund-based term loan rating moved up from BBB- (Stable) to BBB (Positive), and short-term ratings improved from A3 to A3+. The upgrade reflects sustained growth in earnings, cash flows, and operating profit margins, along with an improved financial profile, better liquidity, and stronger debt protection measures. ICRA also cited Wockhardt's healthy market position in India, Europe, and emerging markets, and the launch of its new drug Miqnaf® as supporting factors.
This is a positive signal for shareholders, indicating improved financial health and lower borrowing costs going forward. A credit rating upgrade typically boosts investor confidence and may support a positive sentiment around the stock.